JP2006519225A - 依存症治療用医薬組成物 - Google Patents
依存症治療用医薬組成物 Download PDFInfo
- Publication number
- JP2006519225A JP2006519225A JP2006502684A JP2006502684A JP2006519225A JP 2006519225 A JP2006519225 A JP 2006519225A JP 2006502684 A JP2006502684 A JP 2006502684A JP 2006502684 A JP2006502684 A JP 2006502684A JP 2006519225 A JP2006519225 A JP 2006519225A
- Authority
- JP
- Japan
- Prior art keywords
- drug
- acetylcholine
- type
- pharmaceutical composition
- cocaine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 30
- 206010012335 Dependence Diseases 0.000 title abstract description 7
- 239000003814 drug Substances 0.000 claims abstract description 82
- 229940079593 drug Drugs 0.000 claims abstract description 79
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 claims abstract description 76
- 229960004373 acetylcholine Drugs 0.000 claims abstract description 76
- 206010013663 drug dependence Diseases 0.000 claims abstract description 58
- 208000011117 substance-related disease Diseases 0.000 claims abstract description 48
- 230000009471 action Effects 0.000 claims abstract description 30
- 238000011282 treatment Methods 0.000 claims abstract description 22
- 238000000034 method Methods 0.000 claims abstract description 21
- 239000004480 active ingredient Substances 0.000 claims abstract description 6
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims description 132
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims description 130
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 claims description 84
- 229960005181 morphine Drugs 0.000 claims description 66
- 229960003920 cocaine Drugs 0.000 claims description 65
- 229960003530 donepezil Drugs 0.000 claims description 42
- 230000001713 cholinergic effect Effects 0.000 claims description 37
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical group O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 claims description 26
- 239000000544 cholinesterase inhibitor Substances 0.000 claims description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 19
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 claims description 16
- 229960003980 galantamine Drugs 0.000 claims description 13
- 229940122041 Cholinesterase inhibitor Drugs 0.000 claims description 10
- -1 choline ester Chemical class 0.000 claims description 10
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 claims description 9
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 claims description 9
- 229960001416 pilocarpine Drugs 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 9
- 229930013930 alkaloid Natural products 0.000 claims description 8
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 claims description 7
- 229940025084 amphetamine Drugs 0.000 claims description 7
- AIXQQSTVOSFSMO-RBOXIYTFSA-N Norgalanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CNCC[C@]23[C@@H]1C[C@@H](O)C=C2 AIXQQSTVOSFSMO-RBOXIYTFSA-N 0.000 claims description 6
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 claims description 6
- 150000003797 alkaloid derivatives Chemical class 0.000 claims description 5
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 claims description 5
- 239000000380 hallucinogen Substances 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 102100033639 Acetylcholinesterase Human genes 0.000 claims description 4
- 108010022752 Acetylcholinesterase Proteins 0.000 claims description 4
- RVOLLAQWKVFTGE-UHFFFAOYSA-N Pyridostigmine Chemical compound CN(C)C(=O)OC1=CC=C[N+](C)=C1 RVOLLAQWKVFTGE-UHFFFAOYSA-N 0.000 claims description 4
- 229940022698 acetylcholinesterase Drugs 0.000 claims description 4
- 230000008499 blood brain barrier function Effects 0.000 claims description 4
- 210000001218 blood-brain barrier Anatomy 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims description 4
- 239000000651 prodrug Substances 0.000 claims description 4
- 229940002612 prodrug Drugs 0.000 claims description 4
- 229960002290 pyridostigmine Drugs 0.000 claims description 4
- ASUTZQLVASHGKV-IFIJOSMWSA-N 1668-85-5 Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@H](O)C=C2 ASUTZQLVASHGKV-IFIJOSMWSA-N 0.000 claims description 3
- RSDOPYMFZBJHRL-UHFFFAOYSA-N Oxotremorine Chemical compound O=C1CCCN1CC#CCN1CCCC1 RSDOPYMFZBJHRL-UHFFFAOYSA-N 0.000 claims description 3
- PIJVFDBKTWXHHD-UHFFFAOYSA-N Physostigmine Natural products C12=CC(OC(=O)NC)=CC=C2N(C)C2C1(C)CCN2C PIJVFDBKTWXHHD-UHFFFAOYSA-N 0.000 claims description 3
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 claims description 3
- 229960000451 ambenonium Drugs 0.000 claims description 3
- OMHBPUNFVFNHJK-UHFFFAOYSA-P ambenonium Chemical compound C=1C=CC=C(Cl)C=1C[N+](CC)(CC)CCNC(=O)C(=O)NCC[N+](CC)(CC)CC1=CC=CC=C1Cl OMHBPUNFVFNHJK-UHFFFAOYSA-P 0.000 claims description 3
- WUTYZMFRCNBCHQ-PSASIEDQSA-N cevimeline Chemical compound C1S[C@H](C)O[C@]21C(CC1)CCN1C2 WUTYZMFRCNBCHQ-PSASIEDQSA-N 0.000 claims description 3
- 229960001314 cevimeline Drugs 0.000 claims description 3
- 229960001231 choline Drugs 0.000 claims description 3
- 229960001952 metrifonate Drugs 0.000 claims description 3
- 229960002362 neostigmine Drugs 0.000 claims description 3
- LULNWZDBKTWDGK-UHFFFAOYSA-M neostigmine bromide Chemical compound [Br-].CN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 LULNWZDBKTWDGK-UHFFFAOYSA-M 0.000 claims description 3
- 229960001697 physostigmine Drugs 0.000 claims description 3
- PIJVFDBKTWXHHD-HIFRSBDPSA-N physostigmine Chemical compound C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C PIJVFDBKTWXHHD-HIFRSBDPSA-N 0.000 claims description 3
- VZELUFSMNDBCBO-UHFFFAOYSA-N pyridin-3-yl n,n-dimethylcarbamate Chemical compound CN(C)C(=O)OC1=CC=CN=C1 VZELUFSMNDBCBO-UHFFFAOYSA-N 0.000 claims description 3
- 229960004136 rivastigmine Drugs 0.000 claims description 3
- 229960001685 tacrine Drugs 0.000 claims description 3
- 229940124597 therapeutic agent Drugs 0.000 claims description 3
- NFACJZMKEDPNKN-UHFFFAOYSA-N trichlorfon Chemical compound COP(=O)(OC)C(O)C(Cl)(Cl)Cl NFACJZMKEDPNKN-UHFFFAOYSA-N 0.000 claims description 3
- RRGMXBQMCUKRLH-CTNGQTDRSA-N [(3ar,8bs)-3,4,8b-trimethyl-2,3a-dihydro-1h-pyrrolo[2,3-b]indol-7-yl] n-heptylcarbamate Chemical compound C12=CC(OC(=O)NCCCCCCC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C RRGMXBQMCUKRLH-CTNGQTDRSA-N 0.000 claims description 2
- FWNHTEHWJKUVPG-UHFFFAOYSA-N [3-(dimethylamino)phenyl] n,n-dimethylcarbamate Chemical compound CN(C)C(=O)OC1=CC=CC(N(C)C)=C1 FWNHTEHWJKUVPG-UHFFFAOYSA-N 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 238000012216 screening Methods 0.000 claims description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 1
- 229960003957 dexamethasone Drugs 0.000 claims 1
- 240000004308 marijuana Species 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 description 49
- 210000001009 nucleus accumben Anatomy 0.000 description 47
- 210000004027 cell Anatomy 0.000 description 40
- 230000000694 effects Effects 0.000 description 34
- 238000012360 testing method Methods 0.000 description 23
- 230000007423 decrease Effects 0.000 description 22
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 22
- 230000001419 dependent effect Effects 0.000 description 21
- 230000003340 mental effect Effects 0.000 description 21
- 239000011780 sodium chloride Substances 0.000 description 19
- 230000001143 conditioned effect Effects 0.000 description 18
- 230000003750 conditioning effect Effects 0.000 description 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 17
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 14
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 208000022497 Cocaine-Related disease Diseases 0.000 description 12
- 201000006145 cocaine dependence Diseases 0.000 description 12
- 230000002637 immunotoxin Effects 0.000 description 12
- 229940051026 immunotoxin Drugs 0.000 description 12
- 239000002596 immunotoxin Substances 0.000 description 12
- 231100000608 immunotoxin Toxicity 0.000 description 12
- 229960003638 dopamine Drugs 0.000 description 11
- 239000002504 physiological saline solution Substances 0.000 description 11
- 230000002829 reductive effect Effects 0.000 description 11
- 230000002441 reversible effect Effects 0.000 description 11
- 239000000126 substance Substances 0.000 description 9
- 206010000117 Abnormal behaviour Diseases 0.000 description 8
- 230000003542 behavioural effect Effects 0.000 description 8
- 210000004556 brain Anatomy 0.000 description 8
- 229960004127 naloxone Drugs 0.000 description 8
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 8
- 230000035945 sensitivity Effects 0.000 description 8
- 238000011830 transgenic mouse model Methods 0.000 description 8
- 206010063659 Aversion Diseases 0.000 description 7
- 230000001629 suppression Effects 0.000 description 7
- 208000007848 Alcoholism Diseases 0.000 description 6
- 201000007930 alcohol dependence Diseases 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 241000699660 Mus musculus Species 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000003449 preventive effect Effects 0.000 description 5
- 210000004515 ventral tegmental area Anatomy 0.000 description 5
- CFFZDZCDUFSOFZ-UHFFFAOYSA-N 3,4-Dihydroxy-phenylacetic acid Chemical compound OC(=O)CC1=CC=C(O)C(O)=C1 CFFZDZCDUFSOFZ-UHFFFAOYSA-N 0.000 description 4
- 241000218236 Cannabis Species 0.000 description 4
- 108010009685 Cholinergic Receptors Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 4
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 4
- 102000034337 acetylcholine receptors Human genes 0.000 description 4
- QRMZSPFSDQBLIX-UHFFFAOYSA-N homovanillic acid Chemical compound COC1=CC(CC(O)=O)=CC=C1O QRMZSPFSDQBLIX-UHFFFAOYSA-N 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 229940122578 Acetylcholine receptor agonist Drugs 0.000 description 3
- 102000003914 Cholinesterases Human genes 0.000 description 3
- 108090000322 Cholinesterases Proteins 0.000 description 3
- 206010013754 Drug withdrawal syndrome Diseases 0.000 description 3
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 3
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 3
- 229940123257 Opioid receptor antagonist Drugs 0.000 description 3
- 229940127243 cholinergic drug Drugs 0.000 description 3
- 229940048961 cholinesterase Drugs 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 229960003135 donepezil hydrochloride Drugs 0.000 description 3
- XWAIAVWHZJNZQQ-UHFFFAOYSA-N donepezil hydrochloride Chemical compound [H+].[Cl-].O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 XWAIAVWHZJNZQQ-UHFFFAOYSA-N 0.000 description 3
- 230000003291 dopaminomimetic effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000005090 green fluorescent protein Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 210000000653 nervous system Anatomy 0.000 description 3
- 239000002858 neurotransmitter agent Substances 0.000 description 3
- 229960002715 nicotine Drugs 0.000 description 3
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 3
- 239000003401 opiate antagonist Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 2
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 210000002932 cholinergic neuron Anatomy 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 229960001446 distigmine Drugs 0.000 description 2
- GJHSNEVFXQVOHR-UHFFFAOYSA-L distigmine bromide Chemical compound [Br-].[Br-].C=1C=C[N+](C)=CC=1OC(=O)N(C)CCCCCCN(C)C(=O)OC1=CC=C[N+](C)=C1 GJHSNEVFXQVOHR-UHFFFAOYSA-L 0.000 description 2
- AUZONCFQVSMFAP-UHFFFAOYSA-N disulfiram Chemical compound CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 229960002024 galantamine hydrobromide Drugs 0.000 description 2
- QORVDGQLPPAFRS-XPSHAMGMSA-N galantamine hydrobromide Chemical compound Br.O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 QORVDGQLPPAFRS-XPSHAMGMSA-N 0.000 description 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229940086580 naloxone 1 mg Drugs 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 229940127240 opiate Drugs 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000001671 psychotherapy Methods 0.000 description 2
- 239000000018 receptor agonist Substances 0.000 description 2
- 229940044601 receptor agonist Drugs 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000001308 synthesis method Methods 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 description 1
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 1
- 241000234270 Amaryllidaceae Species 0.000 description 1
- 208000029197 Amphetamine-Related disease Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 235000015256 Chionanthus virginicus Nutrition 0.000 description 1
- 108010058699 Choline O-acetyltransferase Proteins 0.000 description 1
- 102100023460 Choline O-acetyltransferase Human genes 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010013142 Disinhibition Diseases 0.000 description 1
- 102000006441 Dopamine Plasma Membrane Transport Proteins Human genes 0.000 description 1
- 108010044266 Dopamine Plasma Membrane Transport Proteins Proteins 0.000 description 1
- 229940121891 Dopamine receptor antagonist Drugs 0.000 description 1
- VWLHWLSRQJQWRG-UHFFFAOYSA-O Edrophonum Chemical compound CC[N+](C)(C)C1=CC=CC(O)=C1 VWLHWLSRQJQWRG-UHFFFAOYSA-O 0.000 description 1
- 241000672609 Escherichia coli BL21 Species 0.000 description 1
- 241001539473 Euphoria Species 0.000 description 1
- 206010015535 Euphoric mood Diseases 0.000 description 1
- 241000234271 Galanthus Species 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108010010914 Metabotropic glutamate receptors Proteins 0.000 description 1
- 102000016193 Metabotropic glutamate receptors Human genes 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 101001071428 Mus musculus Metabotropic glutamate receptor 2 Proteins 0.000 description 1
- UQOFGTXDASPNLL-XHNCKOQMSA-N Muscarine Chemical compound C[C@@H]1O[C@H](C[N+](C)(C)C)C[C@H]1O UQOFGTXDASPNLL-XHNCKOQMSA-N 0.000 description 1
- 208000027626 Neurocognitive disease Diseases 0.000 description 1
- 206010057852 Nicotine dependence Diseases 0.000 description 1
- 239000008896 Opium Substances 0.000 description 1
- 102000001675 Parvalbumin Human genes 0.000 description 1
- 108060005874 Parvalbumin Proteins 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 206010061921 Psychotic disorder due to a general medical condition Diseases 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000025569 Tobacco Use disease Diseases 0.000 description 1
- 206010048010 Withdrawal syndrome Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 229940005530 anxiolytics Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 238000013542 behavioral therapy Methods 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229960004484 carbachol Drugs 0.000 description 1
- AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 239000000064 cholinergic agonist Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 229960002069 diamorphine Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 229960002563 disulfiram Drugs 0.000 description 1
- 239000003210 dopamine receptor blocking agent Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229960003748 edrophonium Drugs 0.000 description 1
- 230000003086 effect on acetylcholine Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000002095 exotoxin Substances 0.000 description 1
- 231100000776 exotoxin Toxicity 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000003371 gabaergic effect Effects 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229940049906 glutamate Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229960003878 haloperidol Drugs 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000009191 jumping Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 210000000627 locus coeruleus Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000011418 maintenance treatment Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000004245 medial forebrain bundle Anatomy 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- NZWOPGCLSHLLPA-UHFFFAOYSA-N methacholine Chemical compound C[N+](C)(C)CC(C)OC(C)=O NZWOPGCLSHLLPA-UHFFFAOYSA-N 0.000 description 1
- 229960002329 methacholine Drugs 0.000 description 1
- 229960001797 methadone Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- PIPAJLPNWZMYQA-YVSFHVDLSA-N methylatropine Chemical compound C[N+]1(C)[C@@H]2CC[C@H]1C[C@@H](C2)OC(=O)[C@@H](CO)c3ccccc3 PIPAJLPNWZMYQA-YVSFHVDLSA-N 0.000 description 1
- 229960005096 methylatropine Drugs 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 208000008013 morphine dependence Diseases 0.000 description 1
- 229960005195 morphine hydrochloride Drugs 0.000 description 1
- XELXKCKNPPSFNN-BJWPBXOKSA-N morphine hydrochloride trihydrate Chemical compound O.O.O.Cl.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O XELXKCKNPPSFNN-BJWPBXOKSA-N 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 230000003551 muscarinic effect Effects 0.000 description 1
- 229960003086 naltrexone Drugs 0.000 description 1
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 description 1
- 230000008035 nerve activity Effects 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229960001027 opium Drugs 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 229940055076 parasympathomimetics choline ester Drugs 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
- 229950010883 phencyclidine Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44986803P | 2003-02-27 | 2003-02-27 | |
| PCT/JP2004/002301 WO2004075916A1 (en) | 2003-02-27 | 2004-02-26 | Pharmaceutical composition for treatment of drug dependence |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006519225A true JP2006519225A (ja) | 2006-08-24 |
| JP2006519225A5 JP2006519225A5 (https=) | 2007-04-12 |
Family
ID=32927586
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006502684A Pending JP2006519225A (ja) | 2003-02-27 | 2004-02-26 | 依存症治療用医薬組成物 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20060058336A1 (https=) |
| EP (1) | EP1603595B1 (https=) |
| JP (1) | JP2006519225A (https=) |
| AT (1) | ATE487492T1 (https=) |
| AU (1) | AU2004216360B2 (https=) |
| CA (1) | CA2516618A1 (https=) |
| DE (1) | DE602004029993D1 (https=) |
| WO (1) | WO2004075916A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050192271A1 (en) * | 2003-07-15 | 2005-09-01 | Hythiam, Inc. | Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse |
| WO2003032914A2 (en) * | 2001-10-17 | 2003-04-24 | Eisai Co., Ltd. | Methods for treating substance abuse with cholinesterase inhibitors |
| WO2006013546A2 (en) * | 2004-07-28 | 2006-02-09 | Ranbaxy Laboratories Limited | Process for the preparation of pure galantamine |
| MX2010001390A (es) * | 2007-08-06 | 2010-08-02 | Synosia Therapeutics Inc | Métodos para el tratamiento de dependencia. |
| KR101037235B1 (ko) | 2009-04-24 | 2011-05-25 | 충남대학교산학협력단 | 노르갈란타민 화합물을 유효성분으로 함유하는 탈모 방지 및 발모 개선용 조성물 |
| US20120129838A1 (en) * | 2009-04-24 | 2012-05-24 | The Industry & Academic Cooperation In Chungnam National University | Composition for Preventing and Treating Alopecia Disorder Containing Morgalanthamine Compounds as an Active Ingredient |
| KR101037237B1 (ko) | 2009-04-24 | 2011-05-25 | 충남대학교산학협력단 | 노르갈란타민 화합물을 유효성분으로 함유하는 탈모 질환의 예방 및 치료용 조성물 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08505633A (ja) * | 1993-01-23 | 1996-06-18 | エル テー エス ローマン テラピー・システーメ ゲー．エム．ベー．ハー ウント コンパニー カー．ゲー | ニコチン依存症治療のための薬学的処方 |
| JPH09506371A (ja) * | 1994-04-29 | 1997-06-24 | ファイザー インク． | 神経伝達物質放出増強薬としての新規な非環式および環式アミド類 |
| JPH11505519A (ja) * | 1995-03-17 | 1999-05-21 | エルティエス ローマン テラピー−ズュステーメ ゲーエムベーハー | ガランタミンの分離方法 |
| JPH11171861A (ja) * | 1997-12-12 | 1999-06-29 | Eisai Co Ltd | ドネペジルの製造法 |
| WO2002085370A1 (de) * | 2001-04-24 | 2002-10-31 | Hf Arzneimittelforschung Gmbh | Verwendung von galanthamin zur behandlung von krankheitserscheinungen des zentralen nervensystems aufgrund von intoxikationen mit psychotropen substanzen |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI95572C (fi) * | 1987-06-22 | 1996-02-26 | Eisai Co Ltd | Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi |
| US5262165A (en) * | 1992-02-04 | 1993-11-16 | Schering Corporation | Transdermal nitroglycerin patch with penetration enhancers |
| US5336675A (en) * | 1991-05-14 | 1994-08-09 | Ernir Snorrason | Method of treating mania in humans |
| EP0584185B1 (en) * | 1991-05-14 | 1999-08-11 | Ernir Snorrason | Treatment of fatigue syndrome with cholinesterase inhibitors |
| US6010715A (en) * | 1992-04-01 | 2000-01-04 | Bertek, Inc. | Transdermal patch incorporating a polymer film incorporated with an active agent |
| US5278176A (en) * | 1992-08-21 | 1994-01-11 | Abbott Laboratories | Nicotine derivatives that enhance cognitive function |
| US5580876A (en) * | 1992-09-21 | 1996-12-03 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists |
| CA2222133C (en) * | 1995-06-07 | 2002-12-24 | Cygnus, Inc. | Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with an estrogen |
| US5824684A (en) * | 1997-02-21 | 1998-10-20 | Synapse Pharmaceuticals International, Inc. | Method for treating drug and alcohol addiction |
| JP2001513497A (ja) * | 1997-08-08 | 2001-09-04 | メドサン、リセルカ エス．アール．エル． | 胃分泌過多および腎損傷の予防作用を有する抗炎症剤の製造のための化合物２−メトキシフェニル−１−メチル−５ｐ−メチルベンゾイル−ピロール−２−アセトアミドアセテートの使用 |
| GB9716879D0 (en) * | 1997-08-08 | 1997-10-15 | Shire Int Licensing Bv | Treatment of attention deficit disorders |
| US5948433A (en) * | 1997-08-21 | 1999-09-07 | Bertek, Inc. | Transdermal patch |
| DE19738855C2 (de) * | 1997-09-05 | 2001-01-04 | Lohmann Therapie Syst Lts | Transdermales therapeutisches System mit haftklebender Reservoirschicht und unidirektional elastischer Rückschicht |
| IL125809A (en) * | 1998-08-17 | 2005-08-31 | Finetech Lab Ltd | Process and intermediates for production of donepezil and related compounds |
| US20030153598A1 (en) * | 2000-07-25 | 2003-08-14 | Raymond Pratt | Methods for treating Parkinson's disease with cholinesterase inhibitors |
| EP1311272B1 (en) * | 2000-03-03 | 2006-11-22 | Eisai Co., Ltd. | Novel methods using cholinesterase inhibitors |
| US20060183776A9 (en) * | 2000-03-03 | 2006-08-17 | Eisai Co., Ltd. | Liquid dosage formulations of donepezil |
| AU2002229101A1 (en) * | 2000-12-20 | 2002-07-01 | Michigan Biotechnology Institute | Soy milk juice beverage |
| WO2003024450A1 (en) * | 2001-09-20 | 2003-03-27 | Eisai Co., Ltd. | Methods for treating prion diseases |
| WO2003032914A2 (en) * | 2001-10-17 | 2003-04-24 | Eisai Co., Ltd. | Methods for treating substance abuse with cholinesterase inhibitors |
| JP2004189706A (ja) * | 2002-12-13 | 2004-07-08 | Eisai Co Ltd | 高度アルツハイマー型痴呆治療剤 |
| US20050018839A1 (en) * | 2003-07-23 | 2005-01-27 | Weiser William Bruce | Electronic device cradle organizer |
-
2004
- 2004-02-26 AU AU2004216360A patent/AU2004216360B2/en not_active Ceased
- 2004-02-26 US US10/493,488 patent/US20060058336A1/en not_active Abandoned
- 2004-02-26 DE DE602004029993T patent/DE602004029993D1/de not_active Expired - Lifetime
- 2004-02-26 JP JP2006502684A patent/JP2006519225A/ja active Pending
- 2004-02-26 CA CA002516618A patent/CA2516618A1/en not_active Abandoned
- 2004-02-26 AT AT04714961T patent/ATE487492T1/de not_active IP Right Cessation
- 2004-02-26 EP EP04714961A patent/EP1603595B1/en not_active Expired - Lifetime
- 2004-02-26 WO PCT/JP2004/002301 patent/WO2004075916A1/en not_active Ceased
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08505633A (ja) * | 1993-01-23 | 1996-06-18 | エル テー エス ローマン テラピー・システーメ ゲー．エム．ベー．ハー ウント コンパニー カー．ゲー | ニコチン依存症治療のための薬学的処方 |
| JPH09506371A (ja) * | 1994-04-29 | 1997-06-24 | ファイザー インク． | 神経伝達物質放出増強薬としての新規な非環式および環式アミド類 |
| JPH11505519A (ja) * | 1995-03-17 | 1999-05-21 | エルティエス ローマン テラピー−ズュステーメ ゲーエムベーハー | ガランタミンの分離方法 |
| JPH11171861A (ja) * | 1997-12-12 | 1999-06-29 | Eisai Co Ltd | ドネペジルの製造法 |
| WO2002085370A1 (de) * | 2001-04-24 | 2002-10-31 | Hf Arzneimittelforschung Gmbh | Verwendung von galanthamin zur behandlung von krankheitserscheinungen des zentralen nervensystems aufgrund von intoxikationen mit psychotropen substanzen |
Non-Patent Citations (4)
| Title |
|---|
| JPN6010012958, ＷＯＮＧ， Ｃ．−Ｌ． ｅｔ ａｌ, "Ｆｕｒｔｈｅｒ ｓｔｕｄｉｅｓ ｏｎ ｔｈｅ ｒｏｌｅ ｏｆ ｃｈｏｌｉｎｅｒｇｉｃ ｍｅｃｈａｎｉｓｍｓ ｉｎ ｔｈｅ ｄｅｖｅｌｏｐｍｅｎｔ ｏｆ ｉｎｃｒｅａｓｅｄ ｎａｌｏｘｏｎｅ ｐｏｔｅｎ", ＥＵＲＯＰＥＡＮ ＪＯＵＲＮＡＬ ＯＦ ＰＨＡＲＭＡＣＯＬＯＧＹ, 1979, ｖｏｌ．５６， ｎｏ．１−２, ｐ．１１５−１２１ * |
| JPN6010012959, ＫＲＵＳＺＥＷＳＫＡ， Ａ． ｅｔ ａｌ, "Ｔｈｅ ｒｏｌｅ ｏｆ ａｃｅｔｙｌｃｈｏｌｉｎｅ ｉｎ ｔｈｅ ｄｅｖｅｌｏｐｅｍｅｎｔ ｏｆ ｐｈｙｓｉｃａｌ ｍｏｒｐｈｉｎｅ ｄｅｐｅｎｄａｎｃｅ ｉｎ ｒａｔｓ", Ａｃｔａ Ｐｏｌｉｎｉａｅ Ｐｈａｒｍａｃｅｕｔｉｃａ, 1984, ｖｏｌ．４１， ｎｏ．３, ｐ．３８１−３８４ * |
| JPN7010000726, ＢＯＲＯＷＳＫＩ， Ｔ． Ｂ． ｅｔ ａｌ, "Ｔｈｅ ｅｆｆｅｃｔｓ ｏｆ ｔａｃｒｉｎｅ ｏｎ ｃｏｃａｉｎｅ ｓｅｌｆ−ａｄｍｉｎｉｓｔｒａｔｉｏｎ ｉｎ ｒａｔｓ： ａ ｐｏｔｅｎｔｉａｌ ｐｈａｒｍａｃｏｔｈｅｒａｐｙ ｆｏｒ ｃｏｃａｉ", ＳＯＣＩＥＴＹ ＦＯＲ ＮＥＵＲＯＳＣＩＥＮＣＥ, 2000, ｖｏｌ．２６， ｎｏ．１−２, ＃２９３．１８ * |
| JPN7010000727, ＭＡＪＥＷＳＫＡ， Ｍ． Ｄ． ｅｔ ａｌ, "ＤＨＥＡＳ： ａ ｍａｖｅｒｉｃｋ ａｇｅｎｔ ｉｎ ｃｏｃａｉｎｅ ｄｅｐｅｎｄｅｎｃｅ", ＳＯＣＩＥＴＹ ＦＯＲ ＮＥＵＲＯＳＣＩＥＮＣＥ ＡＢＳＴＲＡＣＴＳ, 2000, ｖｏｌ．２６， ｎｏ．１−２, ＃６８１．３ * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1603595B1 (en) | 2010-11-10 |
| CA2516618A1 (en) | 2004-09-10 |
| AU2004216360A2 (en) | 2004-09-10 |
| DE602004029993D1 (de) | 2010-12-23 |
| ATE487492T1 (de) | 2010-11-15 |
| WO2004075916A1 (en) | 2004-09-10 |
| AU2004216360B2 (en) | 2009-09-17 |
| EP1603595A4 (en) | 2008-04-16 |
| AU2004216360A1 (en) | 2004-09-10 |
| EP1603595A1 (en) | 2005-12-14 |
| US20060058336A1 (en) | 2006-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2224917B1 (en) | Composition comprising nicotine and opipramol and use thereof | |
| JPH06507617A (ja) | 疲労症候群の治療 | |
| WO1996009044A1 (en) | Compositions useful for the preparation of medicines for treating a variety of intractable disorders | |
| JP2009509975A (ja) | 薬物嗜癖および行動嗜癖を治療するためのイブジラストの使用 | |
| CA2942638A1 (en) | Method for noribogaine treatment of addiction in patients on methadone | |
| EP2340254B1 (en) | Compositions and methods for treating epilepsy | |
| Khatri et al. | Xylazine suppresses fentanyl consumption during self-administration and induces a unique sex-specific withdrawal syndrome that is not altered by naloxone in rats. | |
| JPH11501282A (ja) | コリン受容体作用薬及び拮抗薬としてのエピバチジン及びその誘導体 | |
| Keegan | Muscle relaxants and neuromuscular blockade | |
| WO2002102388A2 (de) | Wirkstoffkombination von z.b. galanthamin oder desoxypeganin mit z.b. acamprosat oder memantin gegen sucht wie z.b. alkoholismus | |
| JP2006519225A (ja) | 依存症治療用医薬組成物 | |
| JP6629464B2 (ja) | 純粋な５−ｈｔ６受容体アンタゴニスト、アセチルコリンエステラーゼ阻害剤及びｎｍｄａ受容体アンタゴニストの３種類の組合せ | |
| US20070281924A1 (en) | MIF inhibitors for treating neuropathic pain and associated syndromes | |
| EA036347B1 (ru) | Комбинация чистых антагонистов 5-ht6 рецепторов с ингибиторами ацетилхолинэстеразы | |
| JP7265526B2 (ja) | てんかん治療剤 | |
| US20240050427A1 (en) | Treatments for obsessive compulsive disorder | |
| CN101678010B (zh) | 包含(R)-螺[1-氮杂二环[2.2.2]辛烷-3,2’(3’H)-呋喃并[2,3-b]吡啶](AZD0328)的组合物及其在制备治疗阿耳茨海默氏病、ADHD和认知功能障碍的药物中的用途 | |
| KR101442295B1 (ko) | 실로스타졸을 포함하는 통합 실조증 치료제 | |
| CN113573711A (zh) | 治疗药物或酒精依赖性的方法 | |
| CZ27299A3 (cs) | Způsob léčení bipolární afektivní poruchy | |
| US20230201217A1 (en) | 18-mc for treatment of substance use disorders | |
| JP2005306882A (ja) | 感情的不安定の治療のための医薬の製造に有用な組成物 | |
| KR20140130695A (ko) | 섬유근육통 및 만성 피로 증후군을 치료하기 위한 (1r,4r)-6''-플루오로-(N-메틸- 또는 N,N-디메틸-)-4-페닐-4'',9''-디하이드로-3''H-스피로-[사이클로헥산-1,1''-피라노[3,4,b]인돌]-4-아민 | |
| JP4372723B2 (ja) | 慢性疼痛の治療のための医薬の製造に有用な組成物 | |
| EP0821958A2 (en) | Use of 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine (xanomeline) for treating excessive aggression |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070220 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070220 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20070220 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20070727 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20070727 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100316 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100427 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100608 |